Key facts
- This page summarizes Daniel Aghion's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 Nov 2026, 21:11.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Award
Additional SEC filing notes
Footnote F1
On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 72,780 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual Board awards for fiscal years 2027 and 2028. Of these shares, 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2027, and 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2028, in each case subject to the reporting person's continued service. No annual Board award will be granted to the reporting person for fiscal year 2028.
Footnote F2
On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 2,890 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's fiscal year 2027 committee awards, which vest in four substantially equal quarterly installments beginning April 1, 2027, subject to the reporting person's continued service.